NCT00000162

Brief Summary

To determine whether scatter argon laser photocoagulation can prevent the development of neovascularization. To determine whether peripheral scatter argon laser photocoagulation can prevent vitreous hemorrhage. To determine whether macular argon laser photocoagulation can improve visual acuity in eyes with macular edema reducing vision to 20/40 or worse.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 1977

Completed
22.2 years until next milestone

First Submitted

Initial submission to the registry

September 23, 1999

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 24, 1999

Completed
Last Updated

June 24, 2005

Status Verified

October 1, 1999

First QC Date

September 23, 1999

Last Update Submit

June 23, 2005

Conditions

Macular DegenerationNeovascularization, PathologicVitreous Hemorrhage

Interventions

Macular Argon Laser PhotocoagulationPROCEDURE
Peripheral Scatter Argon Laser PhotocoagulationPROCEDURE
Scatter Argon Laser PhotocoagulationPROCEDURE

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Patients with three types of diagnoses were accepted: 1. major BVO without neovascularization; 2. major BVO with neovascularization; 3. BVO with macular edema and reduced vision. All patients must have had onset of signs and/or symptoms of BVO less than 18 months before the initial visit, vision of 5/200 or better, and sufficient clarity of the ocular media to permit confirmation of the condition with fundus photography. Other eligibility criteria apply to each of the three major groups as well as special cases such as the occurrence of bilateral disease.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Related Publications (2)

  • Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol. 1984 Sep 15;98(3):271-82. doi: 10.1016/0002-9394(84)90316-7.

    PMID: 6383055BACKGROUND

  • Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol. 1986 Jan;104(1):34-41. doi: 10.1001/archopht.1986.01050130044017.

    PMID: 2417579BACKGROUND

MeSH Terms

Conditions

Macular DegenerationNeovascularization, PathologicVitreous Hemorrhage

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye DiseasesMetaplasiaPathologic ProcessesPathological Conditions, Signs and SymptomsEye HemorrhageHemorrhage

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Purpose
TREATMENT
Sponsor Type
NIH

Study Record Dates

First Submitted

September 23, 1999

First Posted

September 24, 1999

Study Start

July 1, 1977

Last Updated

June 24, 2005

Record last verified: 1999-10